NASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis $0.49 +0.02 (+3.16%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Estrella Immunopharma Stock (NASDAQ:ESLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Estrella Immunopharma alerts:Sign Up Key Stats Today's Range$0.46▼$0.4750-Day Range$0.43▼$0.7852-Week Range$0.43▼$3.15Volume2,393 shsAverage Volume96,626 shsMarket Capitalization$21.32 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell immunotherapies for cancer and potentially other serious diseases. Its research centers on genetically engineered T cells designed to recognize and attack disease-associated targets. The company’s primary development focus is its CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy programs. These therapies are intended to treat certain B-cell malignancies by directing a patient’s immune cells against CD19, a protein commonly found on malignant B cells. Estrella is working to advance its candidates through preclinical and clinical development while seeking to improve the effectiveness, durability and safety of CAR-T treatment. Publicly available information provides limited detail about the company’s commercial operations, geographic reach and leadership beyond its focus on developing immunotherapies. Estrella does not appear to have an established commercial product portfolio, and its programs remain centered on research and development.AI Generated. May Contain Errors. Read More Estrella Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreESLA MarketRank™: Estrella Immunopharma scored higher than 32% of companies evaluated by MarketBeat, and ranked 711th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEstrella Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialEstrella Immunopharma has a consensus price target of $8.00, representing about 1,532.7% upside from its current price of $0.49.Amount of Analyst CoverageEstrella Immunopharma has only been the subject of 1 research reports in the past 90 days.Read more about Estrella Immunopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Estrella Immunopharma are expected to decrease in the coming year, from ($0.25) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Estrella Immunopharma is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Estrella Immunopharma is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Estrella Immunopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.38% of the float of Estrella Immunopharma has been sold short.Short Interest Ratio / Days to CoverEstrella Immunopharma has a short interest ratio ("days to cover") of 4.18.Change versus previous monthShort interest in Estrella Immunopharma has recently increased by 31.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEstrella Immunopharma does not currently pay a dividend.Dividend GrowthEstrella Immunopharma does not have a long track record of dividend growth. News and Social Media2.4 / 5News SentimentN/A News SentimentEstrella Immunopharma has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Estrella Immunopharma this week, compared to 1 article on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Estrella Immunopharma is held by insiders.Percentage Held by Institutions0.35% of the stock of Estrella Immunopharma is held by institutions.Read more about Estrella Immunopharma's insider trading history. Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESLA Stock News HeadlinesEstrella’s EB103 Lymphoma Trial Advances, Keeping High-Risk Cell Therapy Hopes AliveOctober 1 at 12:31 PM | tipranks.comESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 TrialAugust 26, 2026 | finance.yahoo.comHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.October 2 at 1:00 AM | Chaikin Analytics (Ad)Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaAugust 11, 2026 | finance.yahoo.comEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJuly 29, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s LymphomaJuly 24, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's LymphomaJuly 24, 2026 | businesswire.comESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?July 14, 2026 | finance.yahoo.comSee More Headlines ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed this year? Estrella Immunopharma's stock was trading at $1.56 on January 1st, 2026. Since then, ESLA shares have decreased by 68.6% and is now trading at $0.49. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced its earnings results on Thursday, August, 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Estrella Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Children's Place (PLCE). Company Calendar Last Earnings8/13/2026Today10/02/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, ESLA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ESLA CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Estrella Immunopharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+1,532.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.06 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-328.72% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-1.81Miscellaneous Outstanding Shares43,500,000Free Float40,975,000Market Cap$21.32 million OptionableNot Optionable Beta0.93 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ESLA) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
